BUCHAREST, Romania – May 26, 2026 – A landmark merger announced today between cardiology leader MONZA-ARES and top neurosurgery center Brain Institute is set to create one of Romania’s largest private healthcare platforms, a move poised to significantly reshape the country’s market for complex medical care. Backed by the U.S.-based private equity firm Highlander Partners, the new consolidated group will focus on high-acuity surgical procedures, expanding beyond its core specialties into a comprehensive network for advanced medicine.
A New Force in a Growing Market
The combination brings two of Romania’s most respected private medical operators under a single umbrella. MONZA-ARES has established a national network of seven centers specializing in interventional cardiology and cardiovascular surgery, while Brain Institute has been a pioneer in minimally invasive neurosurgery since its founding in 2013. The merger formalizes a long-standing partnership, as Brain Institute has historically operated within Monza Hospital, the group’s flagship facility in Bucharest.
“The merger signed today is the natural next step,” said Dr. Sergiu Stoica, Head of Neurosurgery and main shareholder of Brain Institute, noting that the move will “strengthen Monza Hospital’s operations and enable us to further accelerate investments in technology and deliver high-quality, innovative care.”
This consolidation comes as Romania’s private healthcare sector experiences rapid growth. Patients, often facing long wait times and outdated infrastructure in the public system, are increasingly turning to private providers like MedLife, Regina Maria, and Sanador. The newly formed MONZA-ARES Group is now positioned to compete directly with these established giants, not just in volume but specifically in the high-margin, high-complexity surgical domain. The group’s stated ambition is to more than double its hospital operations in the next three to five years and establish Monza Hospital as a “reference center for complex surgery in Central and Eastern Europe,” according to General Manager Adrian Demusca.
The deal is a textbook execution of the “buy and build” strategy favored by its majority owner, Highlander Partners. The Dallas-based firm, which holds over $3 billion in assets, acquired a majority stake in ARES in 2019 and has a history of investing in and expanding healthcare assets across Central Europe, including Poland’s MEDI-System.
“We are excited to bring together MONZA-ARES and Brain Institute — two private operators dedicated to medical innovation,” said Dr. Geanina Durigu, CEO of the MONZA-ARES Group. The expanded group will now offer services in ENT, pediatric orthopedics, thoracic surgery, and gynecology, leveraging the combined expertise to build a national platform for patients with chronic and complex conditions across its facilities in Bucharest, Cluj-Napoca, Constanța, and other cities.
The Impact on Patient Care: Access, Quality, and Cost
For Romanian patients, the merger presents a double-edged sword of increased access and potential cost implications. On one hand, the consolidation promises a significant enhancement in the quality and availability of specialized medical care. By pooling elite medical teams and benefiting from substantial private equity investment, the group can acquire cutting-edge technology and expand its geographical footprint, potentially bringing advanced surgical options to regions with limited access.
The private sector is widely perceived as offering a higher standard of care and greater patient comfort, and this new entity aims to build on that reputation. The focus on high-complexity, minimally invasive procedures could mean better outcomes and faster recovery times for patients undergoing everything from heart surgery to complex spinal operations.
However, this expansion comes at a price. Private healthcare in Romania, while sought after for its quality, remains significantly less affordable than the public system. With private health insurance covering only a small fraction of the population—around 3.6% in 2023—most patients pay for private services out-of-pocket. As the new MONZA-ARES Group solidifies its market position, its increased pricing power could place these advanced treatments further out of reach for the average citizen. Studies in other markets have shown that hospital consolidation can lead to higher patient costs, a concern that will loom over this new entity’s growth strategy.
A Blueprint for Physician-Led Growth?
A standout feature of the transaction is the direct financial involvement of the medical staff. “We are also pleased that many doctors from our combined teams have chosen to become shareholders as part of this merger,” stated Dr. Durigu. This physician-shareholder model is being touted as a key strength, intended to align the financial interests of the practitioners with the long-term success of the hospitals.
Dr. Adrian Stroilescu, a Co-Managing Partner at Highlander Partners, called it “the kind of physician-shareholder team that any healthcare investor would aspire to have,” suggesting it provides a strong foundation for growth. In theory, this model fosters a culture of excellence, as doctors who are also owners have a vested interest in maintaining high clinical standards and ensuring patient satisfaction. It can also enhance clinical autonomy, allowing medical professionals to shape care protocols and invest in quality without purely corporate pressures.
Yet, this model is not without its challenges, particularly within a private equity framework where returns on investment are paramount. The American Medical Association and other bodies have raised concerns about corporate investment in medicine, warning of potential conflicts between a physician’s duty to the patient and a company’s fiduciary duty to its shareholders. Maintaining a balance where clinical decisions are shielded from profit-driven motives will be a critical test for the new group’s governance structure. How this dynamic plays out could set a precedent for similar healthcare ventures across Central and Eastern Europe.
Navigating the Regulatory Hurdles
Before its ambitious expansion plans can be fully realized, the merger will almost certainly face review by the Romanian Competition Council (RCC). The RCC actively monitors M&A activity, especially in critical sectors like healthcare, to prevent the formation of monopolies that could harm consumers. Given the new group’s stated goal of becoming a leading national platform, regulators will closely examine its combined market share in specialties like cardiology and neurosurgery.
Precedent suggests the deal has a strong chance of approval. The RCC has authorized other major healthcare consolidations in recent years, including Medicover’s acquisition of Synlab’s local operations and the Regina Maria group’s takeover of Ponderas Hospital. In these cases, the council concluded that the transactions did not significantly impede competition.
The MONZA-ARES Group will need to convince regulators that the merger’s benefits—such as enhanced medical innovation, improved service quality, and greater investment in the national healthcare infrastructure—outweigh any potential anti-competitive risks. The authority will analyze the deal’s impact on patient choice, service pricing, and overall market dynamics. The outcome of the council’s review will be a critical next step in shaping the future of specialized private healthcare in the country.